Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + prilocaine is a fixed-dose combination of two amide-type local anesthetics. Both agents act by blocking voltage-gated sodium channels in neuronal cell membranes, thereby inhibiting the initiation and conduction of nerve impulses. This results in reversible local anesthesia (numbing) at the site of application. The combination is most commonly formulated as a topical cream or patch (e.g., EMLA cream), used for dermal anesthesia prior to minor procedures such as intravenous catheter insertion, blood sampling, superficial surgical interventions, skin grafts, laser hair removal, tattooing preparation, and cleansing or debridement of leg ulcers. It can also be used on genital mucosa for minor procedures or to treat premature ejaculation via topical spray formulations[1][6][9]. Onset and duration depend on dose and application time; effective anesthesia typically requires 1–2 hours under occlusion for intact skin[1][6]. Systemic absorption is generally low but increases with larger doses or compromised skin integrity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + prilocaine.